# Monitoring of Piperacillin-Tazobactam and Meropenem Plasmatic Levels in Critical Patients

> **NCT04257838** · — · UNKNOWN · sponsor: **Fundación Pública Andaluza para la gestión de la Investigación en Sevilla** · enrollment: 200 (estimated)

## Conditions studied

- Sepsis
- Septic Shock

## Interventions

- **DRUG:** Piperacillin/tazobactam or Meropenem

## Key facts

- **NCT ID:** NCT04257838
- **Lead sponsor:** Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-15
- **Primary completion:** 2020-12-15
- **Final completion:** 2021-03-15
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04257838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04257838, "Monitoring of Piperacillin-Tazobactam and Meropenem Plasmatic Levels in Critical Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04257838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*